Patent Application
20100062037
The present invention relates to subcutaneous implants releasing an active principle over an extended period of time, containing an active ingredient dispersed in a polymeric matrix of PLGA, obtained by grinding an extruded product of a blend of at least two PLGA having different lactic acid/glycolic acid molar ratios and different weight average molecular weights, a PLGA and PLA having different weight average molecular weight and the relative process for preparing said implants.
Many therapeutic agents are rapidly metabolized and eliminated by the human or mammalian organism, therefore requiring frequent administration of the drug with the aim of maintaining an adequate therapeutic concentration.
The advantage of using implants containing controlled release drugs is well known in the state of the art.
Among the numerous subcutaneous implants known in the art, those described in WO00/33809 represent a net improvement with reference to previous subcutaneous implants containing, as the active principle, a polypeptide dispersed in a matrix of polylactic-glycolic acid in that they are able to release the aforesaid active principle in 6 months. The subcutaneous implants described in said previous patent application differ also in that they present an essentially triphasic and not biphasic release profile, namely a release by pure diffusion, controlled diffusion following swelling and release by polymer degradation
This progression therefore allows for an extension of release times. In fact when these implants are introduced into an aqueous medium, the water diffuses through the polymeric matrix reaching the peptide particles closest to the surface and subsequently the inner zones.
The implant remains substantially unmodified for about 6 weeks and in this period releases approximately 30% of the peptide.
The duration of this stage of pure diffusion is essentially determined by the level of heterogeneity of the peptide dimensions and the rate is essentially determined by the particle content in the PLGA matrix.
As the active principle presents heterogenous particles of dimensions, a sufficient quantity of peptide remains after the first stage of dissolution and can be released in the successive stages mentioned, that is release by diffusion and swelling, and release by disintegration of the polymer.
All the subcutaneous implants including those previously mentioned suffer from a drawback essentially caused by the fact that once the same are administered in the human body, mainly in the first days they release daily a considerably high overall amount of active principle (in some cases decidedly higher than maximum permitted daily dosages).
This is essentially caused by an immediate dissolution of the active principle, this phenomenon, which does not deplete in subsequent days but some times increases in a scalar progression, is known as initial “burst”. In such cases, therefore, it can be verified that the quantity of drug released from such systems, although if compared to the quantity of total active principle contained in the subcutaneous implants administered is low, can in some cases be considered dangerous if with such an initial burst the maximum permitted daily dosage for such a type of drug is approached or exceeded.
Subcutaneous implants having limited initial release of the active principle and consequently a linearly varying release thereof consisting of:
a core (i) comprising an active principle dispersed in a polymeric matrix of polylactic-glycolic acid (PLGA) copolymer,
a coating in film form (ii), essentially consisting of a lactic-glycolic acid copolymer, and the relative processes for preparing said implants are described in WO 2005/000278 A1.
The Applicant has now unexpectedly found subcutaneous PLGA based implants formulations which overcome the above drawback, namely lack of linearity of the release profile and important initial release rate or burst release, without the necessity to coat said implants as imposed in the aforementioned WO2005/000278 A1.
The present invention therefore relates to subcutaneous implants obtained by extrusion containing an active ingredient dispersed in a PLGA matrix, wherein said matrix is obtained by grinding an extruded product consisting of a blend of:
Such implants result to release their active ingredient on a fairly linear way or, more generally speaking, in a way that could fit in with a specific set of criteria for a particular formulation purpose (e.g. increasing the overall release duration by limiting the initial burst release).
The subcutaneous implants of the present invention preferably contain active principles chosen from the group consisting of: a peptide, an active principle able to increase bone density, an analgesic-narcotic active principle, a steroid hormone, for hormone treatments during menopause and for contraception.
More preferably said peptide is chosen from: avorelin, triptorelin, goserelin and leuprorelin.
The active ingredient able to increase bone density are preferably chosen from: pharmaceutically acceptable bisphosphonic acids and their salts, vitamin D or analogues thereof and sex hormones.
Of these bisphosphonic acids and their pharmaceutically acceptable related salts, we mention for example the compounds of general formula (I):
in which M1, M2, M3 and M4 are monovalent cations and/or H, where said monovalent cations are chosen from alkaline metals, or cations of aliphatic or cycloaliphatic amines, and even more preferably said cations are Na+, we would cite for example those in which R1 and R2 have the meanings given in the following table 1:
Particularly preferred are disodium etidronate, disodium alendronate and disodium pamidronate.
Preferably the sex hormones are selected from the group of estrogens and progestins and of the latter, androgenic progestins are preferably used.
Estrogens are of steroid type preferably chosen from the class consisting of estradiol, estradiol valerate, estradiol cypionate, estrone, estrone sulphate or estrogens of non-steroidal type for example diethylstilbestrol, p-p′-DDT, bis-phenyl-A.
Among male progestins those preferred are chosen from the class consisting of norethindrone, norethinodrel, norgestrel, desogestrel, norgestimate.
As “drugs with narcotic analgesic activity” preferred are morphine and morphinans, i.e. compounds having a chemical structure and activity similar to that of morphine i.e. μ receptor agonists, but also compounds with morphinic-type activity, in other words also μ receptor agonists but with a different chemical structure such as those belonging to the phenylpiperidine class. (Goodman & Gilman's “The pharmacological basis of therapeutics “Ninth Edition Chapter 23 pages 521-555).
As phenylpiperidine μ receptor agonists we cite as preferred at least one active principle chosen from the class consisting of meperidine, fentanyl and relative pharmaceutically acceptable salts, fentanyl congeners, for example sufentanyl, alfentanyl, lofentanyl, carfentanyl, remifentanyl and their pharmaceutically acceptable salts.
The active principle present in the subcutaneous implants of the invention can present heterogeneous dimensions or can have a more homogeneous particle size distribution.
Preferably, when the subcutaneous implants according to the present invention contain a peptide as the active ingredient, they show a heterogeneous size distribution more preferably ranging from 1 to 63 μm or from 1 to 100 μm.
Specifically, when the subcutaneous implants of the invention contain the peptides having the aforesaid heterogenous particles size dimensions, the resulting extruded blended PLGA contained in the subcutaneous implants according to the present invention has preferably a lactic acid/glycolic acid molar ratio ranging from 50/50 and 90:10 and the weight average molecular weight ranges from 50000 to 150000.
The subcutaneous implants according to the present invention are prepared with a process comprising the following steps
We report herewith for illustrative but not limiting purposes the following examples of the subcutaneous implants according to the present invention.
Subcutaneous implants containing 23.5% w/w Goserelin (having particle size distribution ranging from 1 to 63 μm) and PLGA having compositions, L/G molar ratios and molecular weights as defined in the table below are prepared as described in WO00/33809
It is observed from
Subcutaneous implants containing 23.5% w/w Leuprorelin (having particle size distribution ranging from 1 to 100 μm) and PLGA having compositions, L/G molar ratios and molecular weights as defined in the table below are prepared as described in WO00/33809
It is observed that the addition of a higher Glycolide ratio and lower molecular weight PLGA actually leads to lower initial release rate and to a more linear release profile when compared to the one obtained with a single 75/25—high molecular weight PLGA.
Subcutaneous implants containing 27% w/w Leuprorelin (having particle size distribution ranging from 1 to 100 μm) and PLGA having compositions, L/G molar ratios and molecular weights as defined in the table below are prepared as described in WO00/33809
Subcutaneous implants containing 40.0% m/m Fentanyl citrate (having particle size distribution ranging from 1 to 63 μm) and PLGA having compositions, L/G molar ratios and molecular weights as defined in the table below are prepared as described in WO00/33809
This example demonstrates that, if compared to the release profile single PLGA (Form. 4#1), the formulation (Form. 4#2) allows to achieve a more linear release profile also between the seventh and 25th day.
Subcutaneous implants containing 55% m/m Medroxy Progesterone Acetate (having particle size distribution ranging from 1 to 63 μm) and PLGA having compositions, L/G molar ratios and molecular weights as defined in the table below are prepared as described in WO00/33809
As it results from a comparison of the two release profiles it results that the formulation 5# 2 also after the 40th day of the invention a more linear release profile can be achieved with the subcutaneous implants containing a mixture of PLGA than with the subcutaneous implants containing a single PLGA, having a similar L/G molar ratio and an approximately similar average molecular weight.
| Number | Date | Country | Kind |
|---|---|---|---|
| MI2006A001538 | Aug 2006 | IT | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2007/057967 | 8/1/2007 | WO | 00 | 8/18/2009 |
